Massachusetts-based AI biotechnology company Dewpoint Therapeutics has partnered with Glasgow-based biotechnology company Chemify to accelerate the discovery of molecules targeting cancer and neurodegeneration.
This partnership will leverage Chemify's programmable chemistry platform to synthesize novel molecules for Dewpoint's oncology and neurodegeneration pipeline. The collaboration aims to accelerate Dewpoint's chemistry efforts, potentially leading to the acquisition of compounds designed by Chemify, which will receive milestone payments and royalties.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.